On the stock market since 1996, it operates in the world of health and science. It has 40 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
No real growth (4% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
Sales run at $13.8M a year. A small number, but proof the product has real buyers.
A loss of $15.3M against $13.8M in annual sales.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, CSCI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CSCI is a high-risk stock — not yet profitable, and its future rides on its product catching on.